Skip to content
Ep. 396 - China’s first-order innovation episode artwork

Nov 7, 2026 29 min

Ep. 396 - China’s first-order innovation

from BioCentury This Week Hosted by BioCentury

Rising first-in-class innovation, faster IND reviews and deep patient pools are drawing global biotechs to China, even as U.S. outbound investment restrictions loom. In a special edition of the BioCentury This Week podcast recorded live at the 13th BioCentury-BayHelix China Healthcare Summit in Shanghai, BioCentury’s Jeff Cranmer, Simone Fishburn and Josh Berlin are joined by Kali Therapeutics CEO Weihao Xu, Charles River’s Matthew Hewitt and Aerska CEO Jack O’Meara to discuss key themes from the event. The panel assesses what the COINS Act could mean for U.S. investment in China biotech and how investors may adapt, how China’s 30-day IND review and new investigator-initiated trial rules are reshaping clinical strategy, and what dealmaking reveals about the country’s growing first-in-class pipeline. They also preview BioCentury’s East-West Summit in Seoul, March 15-17. View full story: https://www.biocentury.com/article/661483 #ChinaBiotech #COINSAct #ClinicalTrials #FirstInClass #BiotechPartnering 0:00 Live from China Healthcare Summit 5:20 China's Role in Biotech R&D 9:06 What COINS Could Mean for U.S. Investors 11:37 Faster IND Reviews and New IIT Rules 17:27 First-Order Innovation in China To submit a question to BioCentury’s editors, email the BioCentury This Week team at [email protected]. Reach us by sending a text

Episode details come from the podcast's RSS feed.

Embed this episode

Rising first-in-class innovation, faster IND reviews and deep patient pools are drawing global biotechs to China, even as U.S. outbound investment restrictions loom. In a special edition of the BioCentury This Week podcast recorded live at the 13th BioCentury-BayHelix China Healthcare Summit in Shanghai, BioCentury’s Jeff Cranmer, Simone Fishburn and Josh Berlin are joined by Kali Therapeutics CEO Weihao Xu, Charles River’s Matthew Hewitt and Aerska CEO Jack O’Meara to discuss key themes from...

Ready to play

Ep. 396 - China’s first-order innovation

0:00 29:30

Chapters

  1. 0:00 Live from China Healthcare Summit
  2. 5:20 China's Role in Biotech R&D
  3. 9:06 What COINS Could Mean for U.S. Investors
  4. 11:37 Faster IND Reviews and New IIT Rules
  5. 17:27 First-Order Innovation in China

No transcript yet.

Requests help us decide what to transcribe next.

Frequently asked questions

How long is this episode of BioCentury This Week?

This episode is 29 minutes long.

When was this BioCentury This Week episode published?

This episode was published on November 7, 2026.

Can I download this BioCentury This Week episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.